MNLO Menlo Therapeutics Inc

Menlo Therapeutics to Host Conference Call Tomorrow to Discuss Results from Phase 2 Trial of Serlopitant in Patients with Chronic Pruritus of Unknown Origin

Menlo Therapeutics to Host Conference Call Tomorrow to Discuss Results from Phase 2 Trial of Serlopitant in Patients with Chronic Pruritus of Unknown Origin

REDWOOD CITY, Calif., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO), a late-stage biopharmaceutical company, today announced it will host a conference call and webcast on Wednesday, February 26, 2020 at 8:30 am ET (5:30 am PT) to discuss results from the Phase 2 trial of serlopitant in patients with chronic pruritus of unknown origin. The company’s management will be joined on the call by Foamix’s chief executive officer, David Domzalski.

To participate in the live conference call, please call 877-253-4330 (toll-free) or 706-643-0896 (toll) and reference call ID number 2083065. A live webcast of the call can also be accessed by visiting the “Investor” section of the company’s website at . An archived replay of the call will be available for 60 days following the call by dialing 855-859-2056 (toll-free) or 404-537-3406 (toll) and referencing call ID number 2083065.

About Menlo Therapeutics

Menlo Therapeutics Inc. is a late-stage biopharmaceutical company focused on the development of serlopitant, a once-daily oral NK1 receptor antagonist, for the treatment of pruritus. For more information about Menlo Therapeutics, please visit our website at .

Investor Contact:

EN
26/02/2020

Underlying

MNLOMenlo Therapeutics Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Menlo Therapeutics Inc

 PRESS RELEASE
Free
MNLO Menlo Therapeut...

VYNE Therapeutics (formerly Menlo Therapeutics) to Present at the Cant...

VYNE Therapeutics (formerly Menlo Therapeutics) to Present at the Cantor Fitzgerald and H.C. Wainwright Investment Conferences in September BRIDGEWATER, N.J., Sept. 09, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present at the upcoming H.C. Wainwright 22nd Annual Global Investment Conference and the Cantor Fitzgerald Virtual Global Healthcare Conference. H.C. Wainwright Annual Global Investment ConferenceDate:September 14Time:2:30pm Eastern TimeWebcast:  Cantor Fitzgerald Virt...

September 9, 2020 1 EN
 PRESS RELEASE
Free
MNLO Menlo Therapeut...

Menlo Therapeutics Announces Completion of Corporate Name Change to VY...

Menlo Therapeutics Announces Completion of Corporate Name Change to VYNE Therapeutics Will commence trading under new Nasdaq Ticker “VYNE”, September 8, 2020 Company to ring Nasdaq Closing Bell at 4pm ET today BRIDGEWATER, N.J., Sept. 08, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today completed its previously announced corporate name change from Menlo Therapeutics Inc. to VYNE Therapeutics Inc. and the change of its ticker symbol from “MNLO” to “VYNE”.  The name and ticker symbol changes are effective as of the opening of trading today, Se...

September 8, 2020 1 EN
 PRESS RELEASE
Free
MNLO Menlo Therapeut...

Menlo Therapeutics Announces Corporate Name Change to VYNE Therapeutic...

Menlo Therapeutics Announces Corporate Name Change to VYNE Therapeutics Company will commence trading under new ticker “VYNE” on September 8, 2020 Company to ring Nasdaq Closing Bell on September 8 BRIDGEWATER, N.J., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”) announced today it is changing its corporate name to VYNE Therapeutics Inc.  (“VYNE Therapeutics”). In connection with the name change, the Company’s common stock will begin trading under a new ticker symbol “VYNE”.  The name and ticker change will be effective at the openin...

September 2, 2020 1 EN
 PRESS RELEASE
Free
MNLO Menlo Therapeut...

Menlo Reports Second Quarter 2020 Financial Results and Provides Busin...

Menlo Reports Second Quarter 2020 Financial Results and Provides Business Update Conference Call Today at 8:30am Eastern Time BRIDGEWATER, N.J., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced financial results for the second quarter ended June 30, 2020 and provided a corporate update. “The launch of AMZEEQ® earlier in 2020, together with the recent FDA approval for ZILXI™ undersc...

August 6, 2020 1 EN
 PRESS RELEASE
Free
MNLO Menlo Therapeut...

Menlo Therapeutics to Report Second Quarter 2020 Financial Results on ...

Menlo Therapeutics to Report Second Quarter 2020 Financial Results on August 6 BRIDGEWATER, N.J., July 28, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced that it will report its financial results for the second quarter ended June 30, 2020, on Thursday, August 6, before the market opens. Menlo will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the financial results and...

July 28, 2020 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch